RxDoctor Payments Data

Vibeke Green, NP

Nurse Practitioner · Chesapeake, VANPI 1093281057

Payments from drug & device makers

$5,375in general payments, 2019–2025

Across 231 payments — averaging $23.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$757
  • Johnson & Johnson$711
  • Scpharmaceuticals Inc.$524
  • Irhythm Technologies, Inc.$401
  • AstraZeneca$353
  • Pfizer$346
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$5,33299%
  • Education$431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,375 in reported general payments places this provider in the 95th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Medicare billing

Part B allowed, 2024
$30,736
Medicare patients
207
Services billed
820

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban107$138,808
EntrestoSacubitril/Valsartan44$59,979
XareltoRivaroxaban44$43,167
Repatha SureclickEvolocumab28$32,630
MultaqDronedarone Hcl14$12,474
Metoprolol Succinate193$2,554
Ezetimibe26$1,482
Atorvastatin Calcium112$1,320
Flecainide Acetate27$993
Rosuvastatin Calcium62$861
Amiodarone Hcl24$774
Bumetanide22$717
Carvedilol79$607
Amlodipine Besylate104$572
Furosemide102$570

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$346$138,808107 claims
NovartisEntresto$757$59,97944 claims
Johnson & JohnsonXarelto$711$43,16744 claims
Sanofi-aventis U.S. LLCMultaq$37$12,47414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in Chesapeake

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →